Why has the EU opened antitrust proceedings against Sanofi over Efluelda marketing?

The European Commission launched formal antitrust proceedings to examine whether Sanofi’s marketing of its influenza vaccine, Efluelda, for at‑risk seniors may have breached EU competition law. The inquiry will assess potential limits on competitors’ access to senior populations and could shape future vaccine promotion and tender strategies across the industry.